S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
Log in

Global Blood Therapeutics Price Target & Analyst Ratings (NASDAQ:GBT)

$51.90
+0.74 (+1.45 %)
(As of 11/18/2019 04:00 PM ET)
Today's Range
$50.19
Now: $51.90
$52.57
50-Day Range
$46.02
MA: $48.52
$51.05
52-Week Range
$30.15
Now: $51.90
$64.94
Volume709,700 shs
Average Volume766,397 shs
Market Capitalization$3.13 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.57

Analyst Ratings

Global Blood Therapeutics (NASDAQ:GBT) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
13 Wall Street analysts have issued ratings and price targets for Global Blood Therapeutics in the last 12 months. Their average twelve-month price target is $90.92, suggesting that the stock has a possible upside of 75.18%. The high price target for GBT is $150.00 and the low price target for GBT is $50.00. There are currently 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.772.832.832.92
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $90.92$94.64$91.45$91.25
Price Target Upside: 75.18% upside96.22% upside87.22% upside66.33% upside

Global Blood Therapeutics (NASDAQ:GBT) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Global Blood Therapeutics (NASDAQ:GBT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/6/2019Canaccord GenuityInitiated CoverageHold$50.00High
10/17/2019Cantor FitzgeraldReiterated RatingOverweightHigh
10/14/2019SunTrust BanksBoost Price TargetBuy$100.00Low
10/9/2019CowenSet Price TargetBuy$83.00Low
10/9/2019WedbushReiterated RatingBuy$120.00Low
10/9/2019Wells Fargo & CoBoost Price TargetOutperform$96.00 ➝ $104.00Medium
10/9/2019HC WainwrightReiterated RatingBuy$150.00Medium
10/8/2019William BlairReiterated RatingBuyLow
9/5/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
8/9/2019Morgan StanleySet Price TargetHold$60.00Medium
5/29/2019Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$75.00Low
5/9/2019OppenheimerBoost Price TargetOutperform$82.00 ➝ $89.00Medium
2/22/2019GuggenheimInitiated CoverageBuy$75.00Low
8/6/2018Piper Jaffray CompaniesInitiated CoverageOverweight$80.00Low
6/28/2018NomuraBoost Price TargetBuy ➝ Buy$91.00 ➝ $109.00High
4/26/2018Needham & Company LLCReiterated RatingBuy$70.00High
2/13/2018Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$75.00Medium
(Data available from 11/18/2017 forward)
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel